Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study

We previously conducted a phase I clinical trial combining the HLA‐A*2402‐restricted KIF20A‐derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single‐armed, phase II t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Nobuaki, Hazama, Shoichi, Iguchi, Haruo, Uesugi, Kazuhiro, Tanaka, Hiroaki, Hirakawa, Kosei, Aruga, Atsushi, Hatori, Takashi, Ishizaki, Hidenobu, Umeda, Yuzo, Fujiwara, Toshiyoshi, Ikemoto, Tetsuya, Shimada, Mitsuo, Yoshimatsu, Kazuhiko, Shimizu, Ryoichi, Hayashi, Hiroto, Sakata, Koichiro, Takenouchi, Hiroko, Matsui, Hiroto, Shindo, Yoshitaro, Iida, Michihisa, Koki, Yasunobu, Arima, Hideki, Furukawa, Hiroyuki, Ueno, Tomio, Yoshino, Shigefumi, Nakamura, Yusuke, Oka, Masaaki, Nagano, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276830/
https://www.ncbi.nlm.nih.gov/pubmed/27783849
http://dx.doi.org/10.1111/cas.13113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276830/
https://www.ncbi.nlm.nih.gov/pubmed/27783849
http://dx.doi.org/10.1111/cas.13113

Ejemplares similares